Benefits of TIGLUTIK

TIGLUTIK is the only formulation of riluzole approved by the FDA for both oral and PEG tube use. One dose of TIGLUTIK 50 mg (10 mL) (2 teaspoons) is equivalent to one RILUTEK® (riluzole) 50 mg tablet and it is taken twice a day, every 12 hours. TIGLUTIK has a mildly thick consistency and developed to be easy to swallow or use with a PEG tube. Finally, patients no longer have to crush riluzole tablets since TIGLUTIK meets the needs of all people with ALS. Patients should discuss with their physician starting TIGLUTIK as soon as possible.

TIGLUTIK was created by scientific experts to flow smoothly using advanced drug suspension technology. Based on the standards developed by the International Dysphagia Diet Standardization Initiative (IDDSI), TIGLUTIK has a mildly thick consistency (IDDSI criteria Level 2), which is essential for people with ALS who have difficulty swallowing because thin liquids are difficult to take.

Bottle of Tiglutik (riluzole) with syringe

Click here for information to Ask Your Doctor if TIGLUTIK is Right for you.

Benefits of TIGLUTIK

  • Easy to swallow and lessens the risk of choking
  • Flows easily through feeding tubes and eliminates the risk of clogging
  • Mildly thick consistency – flows slower than water
  • One dose contains the same amount of riluzole as a riluzole 50 mg tablet
  • Reduces the need to stop treatment due to difficulties swallowing tablets or having a feed tube
Bottle of Tiglutik (riluzole)



TIGLUTIK (riluzole) is a prescription medicine for the treatment of amyotrophic lateral sclerosis (ALS).

Important Safety Information

  • You should not take TIGLUTIK if you are allergic to any of its ingredients.
  • TIGLUTIK can cause liver injury, including death. Your doctor should do blood tests to check your liver function before and during your treatment and may stop treatment with TIGLUTIK if liver function is not normal. Contact your doctor immediately if you have unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine.
  • Call your doctor immediately if you have a fever, cough, or difficulty in breathing while taking TIGLUTIK.
  • If you miss or skip a dose of TIGLUTIK, do not take any extra dose to make up for those you missed, but take your prescribed dose at the next regularly scheduled time.
  • The most common side effects of TIGLUTIK that occurred during medical studies were numbness/tingling around the mouth, weakness, nausea, decreased lung function, high blood pressure, and abdominal pain. If any side effects become troublesome, contact your doctor.
  • Be sure to tell your doctor and pharmacist about all other health conditions you have and all medicines you are taking, including nonprescription products and vitamins. If you have questions, please talk to your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-332-1088.

Please click here for the Full Prescribing Information.

Intended for U.S. Residents Only

ITF Pharma logo

©2021 ITF Pharma Inc. All rights reserved.  TIGLUTIK is a trademark of ITALFARMACO SA 

3 Paoli Plaza, Suite C
Paoli, PA 19301 United States
Medical/Product Inquiries: 844-763-1198
EDW Pharma US Headquarters: 610-937-6172